B
Brett P. Monia
Researcher at Isis Pharmaceuticals
Publications - 214
Citations - 10319
Brett P. Monia is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Oligonucleotide & Transthyretin. The author has an hindex of 46, co-authored 214 publications receiving 9317 citations. Previous affiliations of Brett P. Monia include Harvard University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Kanji Yamaguchi,Liu Yang,Shannon J. McCall,Jiawen Huang,Xing Xian Yu,Sanjay K. Pandey,Sanjay Bhanot,Brett P. Monia,Yin-Xiong Li,Anna Mae Diehl +9 more
TL;DR: Results from this mouse model would suggest accumulation of triglycerides may be a protective mechanism to prevent progressive liver damage in NAFLD.
Journal ArticleDOI
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson,Márcia Waddington-Cruz,John L. Berk,Michael Polydefkis,Peter J. Dyck,Annabel K. Wang,Violaine Planté-Bordeneuve,Fabio Barroso,Giampaolo Merlini,Laura Obici,Morton A. Scheinberg,Thomas H. Brannagan,William J. Litchy,Carol J. Whelan,Brian M. Drachman,David C. Adams,Stephen B. Heitner,Isabel Conceição,Hartmut H. Schmidt,Giuseppe Vita,Josep M. Campistol,Josep Gamez,Peter D. Gorevic,Edward Gane,Amil M. Shah,Scott D. Solomon,Brett P. Monia,Steven G. Hughes,Jesse Kwoh,Bradley W. McEvoy,Shiangtung W. Jung,Brenda F. Baker,Elizabeth J. Ackermann,Morie A. Gertz,Teresa Coelho +34 more
TL;DR: Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis and improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.
Journal ArticleDOI
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A. Smith,Timothy M. Miller,Koji Yamanaka,Brett P. Monia,Thomas P. Condon,Gene Hung,Christian S. Lobsiger,Christopher M. Ward,Melissa McAlonis-Downes,Hongbing Wei,Ed Wancewicz,C. Frank Bennett,Don W. Cleveland +12 more
TL;DR: Treatment initiated near onset significantly slowed disease progression in a model of amyotrophic lateral sclerosis caused by a mutation in SOD1, suggesting that direct delivery of antisense oligonucleotides could be an effective, dosage-regulatable means of treating neurodegenerative diseases, including ALS, where appropriate target proteins are known.
Journal ArticleDOI
Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease
Varman T. Samuel,Zhen-Xiang Liu,Amy Wang,Sara A. Beddow,John G. Geisler,Mario Kahn,Xian-Man Zhang,Brett P. Monia,Sanjay Bhanot,Gerald I. Shulman +9 more
TL;DR: The hypothesis that PKCepsilon plays a critical role in mediating fat-induced hepatic insulin resistance and represents a novel therapeutic target for type 2 diabetes is supported.
Journal ArticleDOI
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
David B. Savage,Cheol Soo Choi,Varman T. Samuel,Zhen-Xiang Liu,Dongyan Zhang,Amy Wang,Xian-Man Zhang,Gary W. Cline,Xing Xian Yu,John G. Geisler,Sanjay Bhanot,Brett P. Monia,Gerald I. Shulman +12 more
TL;DR: In rats with NAFLD, suppression of both enzymes with a single ASO was required to significantly reduce hepatic malonyl-CoA levels in vivo, lower hepatic lipids, and improve hepatic insulin sensitivity, suggesting that pharmacological inhibition of Acc1 and -2 may be a novel approach in the treatment ofNAFLD.